KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesions.

Caroline L P Muntinga, Peggy J de Vos van Steenwijk, Loes F S Kooreman, Sigrid Regauer, Ziena Abdulrahman, Ruud L M Bekkers, Sjoerd H van der Burg, Gerda Trutnovsky, Edith M G van Esch

J Immunother Cancer 13(10) e012666

PMID41120128
PMCIDPMC12542709
DOI10.1136/jitc-2025-012666
发表日期2025-10-21
入排依据:The study is a Phase III randomized controlled trial with a drug intervention (imiquimod) in an oncology context. However, the reported results do not include a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or Hazard Ratio). The primary outcome described is the rate of clinical response at a fixed time point (16 weeks) and immune microenvironment analysis. Therefore, it does not meet the eligibility criteria for a Kaplan-Meier digitization cohort.
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。
摘要

摘要

Imiquimod is a standard therapy option for vulvar high-grade squamous intraepithelial lesions (vHSIL). In a retrospective study, the pre-existing composition of the immune cell infiltrate was associated with clinical outcome after imiquimod treatment. To validate these findings, an in-depth analysis of the tumor microenvironment was performed on a vHSIL cohort treated with imiquimod in the prospective PITVIN randomized controlled trial (ClinicalTrials.gov identifier: NCT01861535). Pretreatment biopsies of per-protocol patients participating in the PITVIN trial allocated to the imiquimod arm were included (n=38). These were analyzed by multispectral immunofluorescence using two seven-color staining panels for T cell and myeloid cell composition. Samples were scanned with the Vectra imaging microscope. Cell phenotyping was conducted using semi-supervised machine learning. Quick complete response (qCR) (n=27) was defined as absence of clinical lesions at 16 weeks; slow complete response (n=4) as delayed clearance requiring treatment up to 6 months; and non-response (n=7) as persistent histological vHSIL after 6 months, necessitating extended treatment or surgery. Analysis of the tumor immune microenvironment revealed interpatient variability in immune cell infiltration. Immune infiltrate composition in primary and recurrent vHSIL was comparable and this was also reflected by their clinical responsiveness to imiquimod. Higher numbers of intraepithelial CD3+CD8-(CD4+) T helper cells CD4+FoxP3+ regulatory T cells and CD14+ inflammatory myeloid cells and lower numbers of intraepithelial CD33+ immature cells were detected in qCR when compared with other response groups. Importantly, the lesions of complete responders displayed a positive correlation between the numbers of CD4+, CD8+ T cells and CD14+ inflammatory myeloid cells infiltrating the stroma and epithelium, indicative of a coordinated immune response. Slow complete responders displayed increased intraepithelial infiltration of recently activated CD4+PD1+ T cells (p<0.05), but displayed a lower CD14+ and CD68+ myeloid cell infiltration when compared with qCR. The presence of a pre-existing coordinated infiltration of vHSIL lesions with CD4+ T cells, CD8+ T cells and CD14+ inflammatory myeloid cells in patients displaying a CR after imiquimod treatment confirms our previous findings and suggests their use as biomarkers to predict responsiveness, but may also function as biomarkers to reduce or extend treatment duration of imiquimod.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Inclusion flowchart of samples. vHSIL, vulvar high-grade squamous intraepithelial lesion.
非 KM Figure
Figure 2Figure 2. Pre-imiquimod treatment immune microenvironment of T cells and myeloid cells between qCR, sCR and NR. ( A ) Median numbers of intraepithelial and stromal infiltrates of T cells. ( B ) Median numbers of intraepithelial and stromal infiltrates of myeloid cells. No statistically significant differences were observed. NR, non-responder; qCR, quick complete responder; sCR, slow complete responder.
非 KM Figure
Figure 3Figure 3. Visualization of multispectral immunofluorescence from six samples is shown: ( A ) T cell panel, ( B ) Myeloid cell panel. Each pair of images in corresponding positions represents the same sample. The yellow line delineates the epithelium from the stroma. T cell panel: CD3 (red), CD8 (blue), FoxP3 (yellow), Tbet (pink), PD1 (green), TIM3 (orange). Myeloid cell panel: CD68 (red), CD163 (blue), CD11c (yellow), CD14 (turquoise), CD33 (magenta), HLADR (green). NR, non-responder; qCR, quick complete responder; sCR, slow complete responder.
非 KM Figure
Figure 4Figure 4. Pre-existing differences between primary and recurrent vHSIL lesions. ( A ) Median intraepithelial T cell infiltration pretreatment in primary (n=27) and recurrent (n=11) vHSIL. ( B ) Median intraepithelial myeloid cell infiltration pretreatment in primary (n=27) and recurrent (n=11) vHSIL. No statistically significant differences were observed. vHSIL, vulvar high-grade squamous intraepithelial lesion.
非 KM Figure
Figure 5Figure 5. Correlation between the absolute infiltration of T cells and myeloid cells in the epithelium and stroma in complete responders (CR) and non-responders (NR). Complete responders were subdivided into quick complete responders (qCR) and slow complete responders (sCR). The different types of cells are indicated by their markers. Note that FoxP3+ cells only indicate CD3+CD8−Foxp3+ cells. The green boxes indicate the most clear differences between response groups.
非 KM Figure